Debates and discussions on relevant and current issues in the areas of Medicinal Chemistry, Biodiversity and Drug Planning
Coordination: Prof. Adriano D. Andricopulo
An initiative of the Laboratory of Medicinal and Computational Chemistry (LQMC) and the Center for Research and Innovation in Biodiversity and Drugs Discovery (CIBFar-Cepid / FAPESP), of the São Carlos Institute of Physics of USP
25/04 – 14:00 Instituto de Física de São Carlos – Campus 2 – Sala 213
Dr. Caio Vinicius dos Reis
CQMED/SGC-Unicamp
Open Science for the Discovery of New Therapies against Visceral Leishmaniasis
Visceral leishmaniasis is caused by protozoan trypanosomatids of the genus Leishmania and transmitted by the bite of flies of the subfamily Phlebotominae. Current treatments for the disease are not satisfactory and new therapeutic alternatives are needed. The Laboratory of the Structural Genomics Consortium at UNICAMP (SGCUNICAMP) has initiated a small molecule development program to validate aminoacyl tRNA synthetases (AaRS) as therapeutic targets for visceral leishmaniasis. In this seminar, we will present our inhibitor development program based on the structure for AaRS of L. infantum.
25/04 – 14:30 Instituto de Física de São Carlos – Campus 2 – Sala 213
Dra. Carine Cristiane Drewes
Eurofarma – Desenvolvimento Pré-Clínico
Eurofarma Laboratórios: A PreClinical Development Department in a Brazilian Pharmaceutical Company
Eurofarma is a Brazilian pharmaceutical company which has a wide initiative in the P&D field. This initiative includes innovation on similar and generic medicine, incremental innovation, radical innovation via partnerships and proprietary radical innovation. The proprietary radical innovation is a new business strategy for the company and this topic will be addressed during the meeting.